Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Novo Nordisk A/S — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $29.85, while Novo Nordisk A/S trades at $49.6 (market cap $220.53B). The key difference: Novo Nordisk A/S pays a 3.63% dividend while KraneShares Electric Vehicles and Future Mobility pays none. Which is the better fit depends on your goals.
| KARS | NVO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $71.70 |
52-Week Low | $23.61 | $35.29 |
Market Cap | — | $220.53B |
Enterprise Value | — | $239.49B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KARS trades at $29.15, down 0.98% with a bearish technical signal from moving averages and oscillators showing mixed signals. The stock faces headwinds from sector rotation away from traditional automakers toward efficient vehicles, as highlighted by recent news. Financial ratios are unavailable, limiting fundamental clarity, but the electric vehicle ETF context suggests exposure to evolving industry dynamics.
Outlook remains cautious due to technical weakness and sector pressures, though potential exists if EV adoption accelerates. Risks include competitive threats from Chinese automakers and regulatory uncertainty. Investors should await clearer financial data to assess valuation and growth prospects amid shifting market sentiment.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
